FCGR3A and neoplasm: FT516 is designed to express the novel, high-affinity, and non-cleavable valine 158 polymorphism of the CD16 (hnCD16) Fc receptor, which has been modified to prevent downregulation of its expression and enhance its binding to tumor-targeting antibodies.